{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T13:57:07Z","timestamp":1776952627323,"version":"3.51.4"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T00:00:00Z","timestamp":1668988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T00:00:00Z","timestamp":1668988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s10549-022-06798-8","type":"journal-article","created":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T10:03:04Z","timestamp":1669024984000},"page":"369-376","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Evaluation of alpelisib-induced hyperglycemia prophylaxis and associated risk factors in PIK3CA-mutated hormone-receptor positive, human epidermal growth factor-2 negative advanced breast cancer"],"prefix":"10.1007","volume":"197","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3264-1163","authenticated-orcid":false,"given":"Sarah E.","family":"Burnette","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1358-0086","authenticated-orcid":false,"given":"Emily","family":"Poehlein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6060-8443","authenticated-orcid":false,"given":"Hui-Jie","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3326-2715","authenticated-orcid":false,"given":"Jeremy","family":"Force","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly","family":"Westbrook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0619-3267","authenticated-orcid":false,"given":"Heather N.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,21]]},"reference":[{"key":"6798_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A (2020) Cancer Statistics, 2020. CA Cancer J Clin 70:7\u201330","journal-title":"CA Cancer J Clin"},{"key":"6798_CR2","volume-title":"Breast cancer facts & figures 2019\u20132020","author":"American Cancer Society","year":"2019","unstructured":"American Cancer Society (2019) Breast cancer facts & figures 2019\u20132020. American Cancer Society, Inc., Atlanta"},{"key":"6798_CR3","unstructured":"National Comprehensive Cancer Network. Breast Cancer (Version 5.2020). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf. Accessed 26 July 2020"},{"issue":"7418","key":"6798_CR4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"CGA Network","year":"2012","unstructured":"Network CGA (2012) Comprehensive molecular portraits of human breast tumors. Nature 490(7418):61\u201370. https:\/\/doi.org\/10.1038\/nature11412","journal-title":"Nature"},{"issue":"110","key":"6798_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11912-019-0846-7","volume":"21","author":"H Ellis","year":"2019","unstructured":"Ellis H, Ma CX (2019) PI3K inhibitors in breast cancer therapy. Curr Oncol Rep 21(110):1\u20139. https:\/\/doi.org\/10.1007\/s11912-019-0846-7","journal-title":"Curr Oncol Rep"},{"key":"6798_CR6","unstructured":"Piqray (alpelisib) (2019) [prescribing information]. Novartis Pharmaceuticals Corporation, East Hanover"},{"issue":"20","key":"6798_CR7","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","volume":"380","author":"F Andre","year":"2019","unstructured":"Andre F, Ciruelos E, Rubovszky G et al (2019) Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med 380(20):1929\u20131940. https:\/\/doi.org\/10.1056\/NEJMoa1813904","journal-title":"N Engl J Med"},{"key":"6798_CR8","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s10549-020-05618-1","volume":"181","author":"PR Dullinsky","year":"2020","unstructured":"Dullinsky PR, Hurvitz SA (2020) Mechanistic basis for PI3K inhibitor antitumor activity and adverse reactions in advanced breast cancer. Breast Cancer Res Treat 181:233\u2013248. https:\/\/doi.org\/10.1007\/s10549-020-05618-1","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"6798_CR9","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.annonc.2020.05.001","volume":"31","author":"HS Rugo","year":"2020","unstructured":"Rugo HS, Andre F, Yamashita T et al (2020) Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer. Ann Oncol 31(8):1001\u20131010. https:\/\/doi.org\/10.1016\/j.annonc.2020.05.001","journal-title":"Ann Oncol"},{"key":"6798_CR10","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41586-018-0343-4","volume":"560","author":"BD Hopkins","year":"2018","unstructured":"Hopkins BD, Pauli C, Du X et al (2018) Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. Nature 560:499\u2013503. https:\/\/doi.org\/10.1038\/s41586-018-0343-4","journal-title":"Nature"},{"issue":"Supplement 1","key":"6798_CR11","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.2337\/dc21-S002","volume":"44","author":"American Diabetes Association","year":"2021","unstructured":"American Diabetes Association (2021) Classification and diagnosis of diabetes: Standards of medical care in diabetes\u20142021. Diabetes Care 44(Supplement 1):S15\u2013S33. https:\/\/doi.org\/10.2337\/dc21-S002","journal-title":"Diabetes Care"},{"key":"6798_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL et al (2019) The REDCap consortium: Building an international community of software platform partners. J Biomed Inform 95:103208. https:\/\/doi.org\/10.1016\/j.jbi.2019.103208","journal-title":"J Biomed Inform"},{"issue":"2","key":"6798_CR13","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG (2009) Research electronic data capture (REDCap)\u2013a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42(2):377\u2013381. https:\/\/doi.org\/10.1016\/j.jbi.2008.08.010","journal-title":"J Biomed Inform"},{"key":"6798_CR14","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. Published: May 28, 2009. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute"},{"issue":"4","key":"6798_CR15","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(21)00034-6","volume":"22","author":"HS Rugo","year":"2021","unstructured":"Rugo HS, Lerebours F, Ciruelos E et al (2021) Aplelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4\/6 inhibitor (BYLieve): One cohort of a phase 2, multicentre, open-label, non-comparative study. Lancet Oncol 22(4):489\u2013498. https:\/\/doi.org\/10.1016\/S1470-2045(21)00034-6","journal-title":"Lancet Oncol"},{"key":"6798_CR16","doi-asserted-by":"publisher","first-page":"4137","DOI":"10.3748\/wjg.15.4137","volume":"15","author":"S Kawahito","year":"2009","unstructured":"Kawahito S, Kitahata H, Oshita S (2009) Problems associated with glucose toxicity: role of hyperglycemia-induced oxidative stress. World J Gastroenterol 15:4137\u20134142. https:\/\/doi.org\/10.3748\/wjg.15.4137","journal-title":"World J Gastroenterol"},{"issue":"Supplement 1","key":"6798_CR17","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.2337\/dc21-S006","volume":"44","author":"American Diabetes Association","year":"2021","unstructured":"American Diabetes Association (2021) Glycemic targets: Standards of medical care in diabetes\u20142021. Diabetes Care 44(Supplement 1):S73\u2013S84. https:\/\/doi.org\/10.2337\/dc21-S006","journal-title":"Diabetes Care"},{"issue":"Supplement 1","key":"6798_CR18","doi-asserted-by":"publisher","first-page":"S111","DOI":"10.2337\/dc21-S009","volume":"44","author":"American Diabetes Association","year":"2021","unstructured":"American Diabetes Association (2021) Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes\u20142021. Diabetes Care 44(Supplement 1):S111\u2013S124. https:\/\/doi.org\/10.2337\/dc21-S009","journal-title":"Diabetes Care"},{"key":"6798_CR19","unstructured":"Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant (EPIK-B4). ClinicalTrials.gov identifier: NCT04899349. Updated December 7, 2021. Accessed 28 Jan 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04899349."}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-022-06798-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-022-06798-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-022-06798-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T05:28:37Z","timestamp":1672982917000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-022-06798-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,21]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["6798"],"URL":"https:\/\/doi.org\/10.1007\/s10549-022-06798-8","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,21]]},"assertion":[{"value":"23 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"H Moore is an active consultant for Novartis Pharmaceuticals and serves on the EPIK-B4 steering committee and is active PI of EPIK-B4 at Duke University Hospital. S Burnette, HJ Lee, and E Poehlein, J Force, and K Westbrook have no conflicts of interest to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All study protocols were reviewed and approved by Duke University Health System\u2019s Institutional Review Board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}